Watton Corey Michael
Known title: DirectorCIK: 0001975404
Watton Corey Michael's purchase track record
How the stock did after each of Watton Corey Michael's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
5
of 5 since May 30, 2023
Stock higher 6 months later
20%
3 months: 40%
Median 6-month return
-8.0%
3 months: -0.6%
Beat the S&P 500
20%
median -14.0% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/28/2025 | ZVRA | $2K | +14.6% | +24.5% | +19.0% |
| 10/11/2024 | ZVRA | $4K | -0.6% | -15.4% | -7.8% |
| 6/23/2023 | ZVRA | $2K | -12.1% | -10.1% | +9.3% |
| 6/9/2023 | ZVRA | $2K | -4.7% | -8.0% | +7.1% |
| 5/30/2023 | ZVRA | $2K | +4.9% | -5.7% | +8.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ZVRA | ▼ Sell | Open Market | 12,300 | $138K | 8/10/2026 | View on chart |
| ZVRA | ▲ Buy | Option Exercise | 12,300 | $61K | 8/10/2026 | View on chart |
| ZVRA | ▲ Buy | Open Market | 300 | $2K | 3/28/2025 | View on chart |
| ZVRA | ▲ Buy | Open Market | 500 | $4K | 10/11/2024 | View on chart |
| ZVRA | ▲ Buy | Open Market | 275 | $2K | 6/23/2023 | View on chart |
| ZVRA | ▲ Buy | Open Market | 325 | $2K | 6/9/2023 | View on chart |
| ZVRA | ▲ Buy | Open Market | 400 | $2K | 5/30/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price
Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price. Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.